BOSTON and LAUSANNE, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the second quarter of fiscal 2022 before U.S. markets open on Tuesday, August 9, 2022. SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:30 a.m. EDT / 2:30 p.m. CEST.
The call will be webcast live on the SOPHiA GENETICS Investor Relations website . Additionally, a replay will be available on the website after its completion.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by over 790 hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM , or connect on Twitter , LinkedIn and Instagram . Where others see data, we see answers.
Investor Contact:
Jennifer Pottage
Head of Investor Relations
Jpottage@sophiagenetics.com
Media Contact:
Don Granese
Public Relations
Dgranese@sophiagenetics.com